Yatsen (YSG) Q1 2026 Earnings Call Transcript

Yatsen posted Q1 2026 revenue of $1.02 billion, up 22.5% year over year, driven by 58.5% growth in skincare brands, while gross margin expanded to 80.2% from 79.1%. However, operating expenses rose 32.5% to $918.1 million, pushing operating loss to $99 million and net loss to $61.9 million; operating cash flow also turned negative at $90 million used. Management guided Q2 revenue to $1.2 billion-$1.3 billion, or 10%-20% growth, and highlighted continued investment in R&D, product launches, and AI-driven marketing efficiency.

Analysis

YSG is showing the classic late-stage growth paradox: the brand mix is improving faster than the P&L, which usually means the company is buying future pricing power with present-day margin compression. The key second-order effect is that skincare success is not just additive revenue; it reduces reliance on lower-quality traffic and gives management a chance to reprice the marketing stack around hero products, which can matter more than this quarter’s earnings miss once the funnel stabilizes.

The financing matters more than the headline growth because it de-risks the near-term cash runway while also creating an overhang into the stock. Convertible + warrant capital can be read as institutional validation, but in practice it often suppresses upside until investors can model dilution and the post-financing burn rate; that means the next 1-2 quarters are about proving operating leverage, not celebrating demand momentum.

The market is likely underappreciating how dependent the skincare thesis is on continued TAC inflation cooling. If traffic costs stay elevated, the company’s “AI/data efficiency” narrative becomes a timing tool rather than a structural margin solution. The right tell will be whether S&M as a percent of revenue inflects lower by the next quarter; if not, revenue growth may remain strong while equity value creation leaks into media platforms and channel partners.

Contrarian view: consensus may be over-reading the brand repositioning as a durable margin reset. The more realistic outcome is a 6-12 month transition period where better mix supports gross margin, but operating margin lags because brand-building spend is still front-loaded. That creates a tradeable asymmetry: good top-line prints can coexist with weak cash conversion, which is bullish for suppliers and ad platforms, but not necessarily for the equity unless execution improves quickly.

Key Decisions for Investors

• Avoid chasing YSG common stock immediately; wait 1-2 quarters for evidence that S&M intensity rolls over below ~70% of revenue before adding exposure. Until then, the risk/reward is skewed by dilution and cash burn.
• If holding YSG, consider a short-dated covered call overlay into the next earnings release to monetize elevated implied volatility while the market digests the financing and margin reset.
• Pair trade: long a high-quality digital ad beneficiary / short YSG for 1-3 months if you expect traffic acquisition costs to remain sticky; the thesis is that spend migrates to platforms while YSG bears the conversion cost.
• For higher-risk exposure, buy YSG only on a post-earnings pullback if Q2 revenue lands at the high end of guidance and operating cash burn narrows; that would validate the thesis that hero products are starting to support operating leverage.
• Watch for a relative-value long in suppliers or channel enablers versus YSG if skincare growth continues but profitability lags; the second-order winner is likely to be the ecosystem monetizing the ad/commerce spend, not the retailer itself.